step 7 semaglutide Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Higher-Dose Semaglutide Achieves Historic 21%

doi: 10.1159/000046880

Additionally, GLP-1 RAs were effective in reducing alcohol and substance use and binge eating behaviors

It specifically targets loose, hanging skin that remains on the stomach, back, arms, thighs, and buttocks despite a healthy diet and regular exercise

Therefore, targeting TFEB may be a promising strategy for the treatment of AD

[5] [6] However, retatrutide remains an investigational compound and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for any clinical use

However, diabetic patients taking GLP-1 drugs may face increased risks for both conditions